Market Access News | pharmaphorum

News

FDA clears nasal opioid reversal drug, lifting Indivior

The FDA has approved a new intranasal therapy for treating opioid overdose developed by Opiant Pharma, giving a boost to its new UK owner Indivior.

News

FDA panel vote dashes Intercept’s NASH hopes

Intercept Pharma is facing an uphill battle to get FDA approval of its OCA therapy for non-alcoholic steatohepatitis (NASH) once again, after FDA advisors comprehensively

News

Foundation aims to level health access with digital tech

A new initiative called the Movement Health Foundation (MHF) has been launched with a pledge to encourage greater use of digital technologies to equalise access to healthc

News

CD20 market heats up as FDA OKs AbbVie, Genmab bispecific

AbbVie and partner Genmab have FDA approval for the lead drug in their $3.9 billion cancer

News

FDA clears Vyjuvek as first topical gene therapy

The FDA has approved Krystal Biotech’s gene therapy Vyjuvek for dystrophic epidermolysis bullosa (DEB), a rare genetic disease characterised by fragile skin that can split

News

FDA advisors back Pfizer’s RSV shot for maternal use

An FDA advisory committee has endorsed Pfizer’s respiratory syncytial virus (RSV) vaccine for use in expectant mothers, potentially opening up a niche for the shot, where

FDA clears nasal opioid reversal drug, lifting Indivior

FDA panel vote dashes Intercept’s NASH hopes

Foundation aims to level health access with digital tech

CD20 market heats up as FDA OKs AbbVie, Genmab bispecific

FDA clears Vyjuvek as first topical gene therapy

FDA advisors back Pfizer’s RSV shot for maternal use

Mark Dawson named head of Roche's pRED unit

How to meet your physicians where they are online

News

Editor's Picks